Synovus Financial Corp Acquires Shares of 14,600 Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

Synovus Financial Corp bought a new position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) during the third quarter, HoldingsChannel.com reports. The fund bought 14,600 shares of the company’s stock, valued at approximately $28,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. The Manufacturers Life Insurance Company grew its holdings in shares of Tenaya Therapeutics by 43.2% in the second quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock worth $72,000 after purchasing an additional 7,000 shares during the last quarter. Algert Global LLC bought a new position in Tenaya Therapeutics in the 2nd quarter worth about $74,000. SG Americas Securities LLC purchased a new position in shares of Tenaya Therapeutics during the third quarter worth approximately $49,000. XTX Topco Ltd raised its stake in shares of Tenaya Therapeutics by 51.2% during the third quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock valued at $95,000 after acquiring an additional 16,687 shares in the last quarter. Finally, Panagora Asset Management Inc. bought a new stake in shares of Tenaya Therapeutics during the second quarter valued at approximately $164,000. 90.54% of the stock is currently owned by institutional investors.

Tenaya Therapeutics Trading Up 14.6 %

Shares of NASDAQ:TNYA opened at $1.41 on Friday. The company has a market capitalization of $111.70 million, a PE ratio of -0.98 and a beta of 2.72. Tenaya Therapeutics, Inc. has a 12-month low of $0.99 and a 12-month high of $7.01. The business’s fifty day simple moving average is $2.43 and its 200-day simple moving average is $2.71.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its earnings results on Wednesday, November 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.07. Research analysts predict that Tenaya Therapeutics, Inc. will post -1.35 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on TNYA. Canaccord Genuity Group reissued a “buy” rating and issued a $16.00 price objective on shares of Tenaya Therapeutics in a research note on Friday, October 18th. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Tenaya Therapeutics in a research note on Wednesday. Piper Sandler restated an “overweight” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Chardan Capital reiterated a “buy” rating and set a $18.00 target price on shares of Tenaya Therapeutics in a report on Wednesday. Finally, Leerink Partners reissued an “outperform” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $17.33.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.